Oral Beclomethasone Dipropionate for the Treatment of Steroid-refractory Gastrointestinal Acute Graft-versus-host Disease
Korean Journal of Hematology
;
: 304-309, 2009.
Article
in English
| WPRIM
| ID: wpr-720067
ABSTRACT
Acute graft-versus-host disease (GVHD) is one of the most severe complications following allogeneic stem cell transplantation (SCT), and involvement of the gut has been associated with increased mortality and a poorer response to high-dose systemic corticosteroids. For over a decade, oral beclomethasone dipropionate (BDP) has been studied in the treatment of acute gastrointestinal GVHD, as a monotherapy, or in combination with systemic corticosteroids. Here we report, for the first time in Korea, the efficacy of oral BDP (8 mg/day for 25 days) in 3 adults with acute lymphoblastic leukemia who developed steroid-refractory gastrointestinal GVHD (grade III) after myeloablative conditioning SCT (1 matched sibling transplant, 2 matched unrelated transplants). All patients responded completely to oral BDP treatment. Oral BDP is safe and effective for the control of steroid-refractory acute gastrointestinal GVHD.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Beclomethasone
/
Adrenal Cortex Hormones
/
Transplants
/
Stem Cell Transplantation
/
Siblings
/
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/
Graft vs Host Disease
/
Korea
Limits:
Adult
/
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Korean Journal of Hematology
Year:
2009
Type:
Article
Similar
MEDLINE
...
LILACS
LIS